Mesalamine News
Axcan Reports Fourth Quarter & Year-end 2005 Financial Results
Axcan applied for a Supplemental New Drug Submission to the Therapeutic Products Directorate of Health Canada for a new 750-milligram mesalamine (5-ASA) tablet for the oral treatment of ulcerative colitis in Canada.
MMX Mesalamine Induces Remission Of Ulcerative Colitis
A novel formulation of Multi-Matrix SystemTM (MMX) mesalamine (MesavanceTM) induces remission in patients with active mild-to- moderate ulcerative colitis and is generally well-tolerated at once-daily and twice-daily dosing,...
Asacol Induced Rapid Mucosal Healing in Ulcerative Colitis Patients
A new data analysis shows that Asacol(R) (mesalamine) delayed-release 400 mg tablets (2.4 g/day) and investigational 800 mg mesalamine tablets (4.8 g/day) induced endoscopically measured mucosal healing in patients with...
Multivitamin cuts need for ulcerative colitis treatment
According to a study published in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, a nutritionally complete oral supplement enriched with fish oil, soluble fiber and...
Displaying results 6 to 9 out of 9